ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / SLGL / options
KROS (64) ELDN (37) EVMN (31) SIGA (68) ⌘ Pro Terminal β†’

Sol-Gel Technologies Ltd. (SLGL) Options Positioning, Max Pain & Unusual Sweeps

$65.69 -3.89% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $65.11

Sol-Gel Technologies Ltd. (SLGL) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $215.1M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SLGL Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SLGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $65.69 (-3.89% 1D, market cap $215.1M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SLGL ranks #290 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SLGL compare to KROS and ELDN in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLGL carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 85.0%, cap $213.3M) and ELDN (Eledon Pharmaceuticals Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $212.9M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SLGL?
β–Ό

Per SLGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001684693), Sol-Gel Technologies Ltd. generated $19.4M in revenue (+68.0% YoY), -$6.1M in net income, and $275.0K in free cash flow against $29.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $65.11 (-0.89%)🧬 Dilution Drag (+1.92% YoY Shares)βš™οΈ Cash Engine: 13/20 (C) β€’ 1.4% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (48/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510048
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- Β· Rk D+
Cash (13)Whales (8)SEC (14)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
$103 Bull$63 Base$49 Bear
πŸ“¬ FREE SLGL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SLGL)Realized 20D OHLCV Swing Band: Β±11.6%
Deterministic 5-Pillar Attribution (48/100 Composite)
πŸ” WHY SLGL SCORES 48/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (29% of score)

Altman Z-Score 8.54 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 6/9

β–² #2 Bullish Driver: Cash Engine Quality+13/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 1.4% FCF Margin ($275.0K FCF) & 52% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
56
Grade C$69.50-5.4% Next Q
Q2 (-2Q)
53
Grade C-$65.72+3.7% Next Q
Q3 (-1Q)
51
Grade C-$68.18-3.7% Next Q
Current
48
Grade D$65.69-5.6% Hist 90D Ξ±
Trajectory: C (56) β†’ D (48)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SLGL Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SLGL currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($68.28) and Max Pain ($68.97) forces dealer call-delta covering toward $102.87.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLGLβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSLGL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 48%NO 52%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±11.6%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SLGL)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SLGL.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLGL)

  • βœ“Walkthrough of SLGL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SLGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.95%β–Ό DESCENDING CHANNEL
2026-11-04O $68.35H $68.35L $65.69C $65.69VOL 56.0K
RES: $73.86SUP: $52.68SMA50: $68.28SMA200: $73.98
$96.91$83.79$70.67$57.56$44.44RES $73.86SUP $52.68$65.692026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SLGL Butterfly Map β†’ + Track SLGL β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +68.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SLGL today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SLGL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SLGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLGL)

Health Care Rank #290 of 1015 βš”οΈ KROS vs SLGL Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SLGL vs. KROS, ELDN, EVMN, SIGA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Sol-Gel Technologies Ltd. (SLGL) ranks #290 by composite RQD confidence (48/100, grade D) and #558 by equity capitalization ($215.1M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and β€” gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with SLGL at 48/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SLGL ACTIVE
Sol-Gel Technologies Ltd.
D 48/100 β€” β€” -35.0% -3.89% $215.1M Benchmark Subject
KROS
Keros Therapeutics Inc.
C 64/100 β€” β€” 85.0% -2.54% $213.3M /kros-vs-slgl β†’
ELDN
Eledon Pharmaceuticals Inc.
D- 37/100 β€” β€” -35.0% -5.41% $212.9M /eldn-vs-slgl β†’
EVMN
Evommune Inc.
E 31/100 β€” β€” -35.0% -10.70% $218.1M /evmn-vs-slgl β†’
SIGA
SIGA Technologies Inc.
C+ 68/100 9.8x 68.6% 42.7% -2.96% $212.0M /siga-vs-slgl β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001684693 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sol-Gel Technologies Ltd. (SLGL) reported GAAP revenue of $19.4M (+68.0% vs. FY2024 revenue of $11.5M , and +1147.6% cumulative change since FY2023) , GAAP net income of -$6.1M, operating cash flow of $322.0K, and free cash flow of $275.0K (+102.0% YoY). On the balance sheet, SLGL closed FY2025 with $29.9M in total assets against $0 in total debt (Altman Z-Score: 8.54, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $19.4M -$6.1M $322.0K $275.0K $29.9M β€”
FY2024 (FY) 2024-12-31 $11.5M -$10.6M -$13.9M -$13.9M $35.8M β€”
FY2023 (FY) 2023-12-31 $1.6M -$27.2M -$17.7M -$17.7M β€” β€”

3. SLGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $65.69 (-3.89% 1D, market cap $215.1M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SLGL ranks #290 in composite RQD confidence.

How does SLGL compare to KROS and ELDN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLGL carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, KROS (Keros Therapeutics Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 85.0%, cap $213.3M) and ELDN (Eledon Pharmaceuticals Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $212.9M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SLGL?

Per SLGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001684693), Sol-Gel Technologies Ltd. generated $19.4M in revenue (+68.0% YoY), -$6.1M in net income, and $275.0K in free cash flow against $29.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SLGL trading relative to its 50-day, 200-day, and 52-week technical levels?

SLGL last traded at $65.69 (-3.89% on volume of 55,999 shares), positioning the stock -3.79% below its 50-day simple moving average ($68.28) and -11.21% below its 200-day simple moving average ($73.98). Across its 52-week range of $28.81 to $97.97, SLGL sits at the 53.3% percentile with a 14-day RSI of 44.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±11.6% ($58.07 to $73.31).

Direct Sub-Reports: SLGL RQD Cockpit SLGL 12M Forecast SLGL Earnings & Move SLGL Dividends & DRIP SLGL Insiders & 13F SLGL Whale Options SLGL Profit Sankey SLGL News & Why
ROARABLE RATING BRIEF β€’ RQD 48/100 (D) βœ“ SEC XBRL & RQD VERIFIED

SLGL β€” Sol-Gel Technologies Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Sol-Gel Technologies Ltd. (SLGL) earns a live Roarable RQD composite score of 48/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $65.69 (-3.89% 1D, market capitalization $215.1M).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -38.9%, and free cash flow yield of 0.12%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 8.54, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Sol-Gel Technologies Ltd. Is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry..2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Sol-Gel Technologies Ltd. (SLGL) reported $19.4M in annual revenue (up from $11.5M in FY2024, +68.0% YoY) and -$6.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.6M revenue, -$27.2M net income) through FY2025, SLGL scaled operating cash flow to $322.0K and free cash flow to $275.0K, backed by $29.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 48/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.12% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $28.81 – $97.97 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -38.9% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), SLGL carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can SLGL sustain or expand its -38.9% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $19.4M and free cash flow of $275.0K, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SLGL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SLGL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sol-Gel Technologies Ltd. (SLGL) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SLGL Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SLGL Bull vs. Bear Conversation Board β€” What's Your Call at $65.69?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SLGL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SLGL:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $88.85 (+30.0%)
πŸ“Œ Pinned Debate

A high Altman Z-Score of 8.54 and Debt/Equity of 0.5 indicate balance sheet resilience alongside revenue growth from $1.6M to $19.4M.

Here is why I am bullish on SLGL here at $68.35: A high Altman Z-Score of 8.54 and Debt/Equity of 0.5 indicate balance sheet resilience alongside revenue growth from $1.6M to $19.4M.. Compare SLGL's -38.9% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $64.93 are getting bought.

EarningsSniper πŸ‚ BULL

@MultipleCompression Shorting a 8/20 institutional whale-flow stock at $68.35 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER β€’ Valuation Discipline 🐻 BEARISH 🎯 Target: $51.95 (-24.0%)
Spot @ $68.35

Negative ROIC of -35%, operating margin of -38.9%, and a weak insider conviction score of 5/20 point to unresolved unprofitability.

Sitting on the sidelines or leaning short SLGL above $68.35. Negative ROIC of -35%, operating margin of -38.9%, and a weak insider conviction score of 5/20 point to unresolved unprofitability.. Until Fundamental Cash Engine (13/20) and FCF yield (0.12%) inflect higher, upside is capped near $97.97.

LIVE TAPE